Ad
AGLE - Aeglea BioTherapeutics Stock Trading
About | Aeglea BioTherapeutics Inc. (NASDAQ:AGLE)
None
Quote | Aeglea BioTherapeutics Inc. (NASDAQ:AGLE)
| Last: | $12.01 |
|---|---|
| Change Percent: | 1.54% |
| Open: | $10.87 |
| Close: | $12.01 |
| High: | $12.3399 |
| Low: | $10.69 |
| Volume: | 43,222 |
| Last Trade Date Time: | 11/27/2023 03:00:00 am |
News | Aeglea BioTherapeutics Inc. (NASDAQ:AGLE)
-
2023-11-27 08:59:20 ET More on Aeglea BioTherapeutics Aeglea BioTherapeutics announces 1-for-25 reverse stock split Aeglea BioTherapeutics appoints Burrows as CFO, King-Jones as CLO Seeking Alpha’s Quant Rating on Aeglea BioTherapeutics For further det...
-
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD PR Newswire Company will begin trading on Nasdaq under trading sy...
Message Board Posts | Aeglea BioTherapeutics Inc. (NASDAQ:AGLE)
| Subject | By | Source | When |
|---|---|---|---|
| $AGLE she is green | subslover | investorshub | 06/23/2023 4:17:08 PM |
| AGLE: Interesting points there, Colonel Subs! | Invest-in-America | investorshub | 06/23/2023 1:01:53 PM |
| oh my | The Night Stalker | investorshub | 06/23/2023 4:02:02 AM |
| Now is not the time for most OTC | subslover | investorshub | 06/22/2023 9:55:58 PM |
| Bought .39-.45 sold .75-70, $$$$$ | harry crumb | investorshub | 06/22/2023 9:29:35 PM |
News, Short Squeeze, Breakout and More Instantly...
Aeglea BioTherapeutics Inc. Company Name:
AGLE Stock Symbol:
NASDAQ Market:
Aeglea BioTherapeutics Inc. Website:
Ad
-
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD PR Newswire Company will begin trading on Nasdaq under trading sy...
-
2023-11-20 05:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Continued progress across the Company's potentially best-in-class inflammatory bowel disease (IBD) portfolio SPY001, a half-life extended anti-α4β...